Opendata, web and dolomites

UCRxF

A novel ulcerative colitis treatment - A phase III ready feasibility study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UCRxF project word cloud

Explore the words cloud of the UCRxF project. It provides you a very rough idea of what is the project "UCRxF" about.

line    stockholm    larger    severe    patients    biological    q4    finance    iib    licensing    demonstrated    planning    revenues    science    initiation    action    immunological    immunomodulatory    ulcerative    prior    efficient    clinical    active    2018    preparation    continue    colon    upfront    innovative    medical    karolinska    company    dims    moderate    mechanism    treat    institutet    cure    reported    tested    toxicology    companies    generate    portfolio    milestone    party    fast    uc    preparations    ab    disease    ready    drugs    approved    pharmaceuticals    sweden    license    broad    international    sales    dna    royalties    pharmaceutical    offers    drug    park    commercial    index    additional    business    partnering    diseases    sequences    safety    caused    medication    attractiveness    cobitolimod    asset    debilitating    reinvested    deal    platform    purpose    strategy    compounds    manufacturing    efficacy    acute    payments    colitis    chronic    feasibility    profile    treatment    unmet    inflammation    primary   

Project "UCRxF" data sheet

The following table provides information about the project.

Coordinator
INDEX PHARMACEUTICALS AB 

Organization address
address: TOMTEBODAVAGEN 23A
city: STOCKHOLM
postcode: 171 77
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.indexpharma.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INDEX PHARMACEUTICALS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

InDex Pharmaceuticals AB is a pharmaceutical development company based at the Karolinska Institutet Science Park in Stockholm, Sweden. The company´s primary asset is cobitolimod, which is in late phase clinical development as a new medication to treat moderate to severe active ulcerative colitis (UC); a chronic, debilitating disease with a high unmet medical need. UC is caused by chronic inflammation of the colon, and there is no cure.

Cobitolimod offers a novel and unique mechanism of action for the treatment of UC, and has demonstrated a higher efficacy and better safety profile in clinical studies than what has been reported for currently approved biological drugs. Cobitolimod is part of the broad InDex portfolio of DNA-based ImmunoModulatory Sequences (referred to as DIMS), which have the potential for treatment of various immunological diseases. Cobitolimod is currently being tested in a phase IIb clinical study with top line results expected in Q4 2018.

InDex’s business strategy is to out-license cobitolimod to a larger international pharmaceutical company prior to the initiation of clinical phase III development. This will generate revenues for InDex from upfront and milestone payments as well as royalties from third party sales, which can then be reinvested in the company to finance development of new compounds from the DIMS technology platform.

For clinical phase III, additional manufacturing and toxicology work as well as commercial preparations are essential. The planning and preparation of this work is the purpose of this feasibility study, which is a crucial part of the cobitolimod phase III ready programme, increasing the attractiveness of the asset in partnering discussions with pharmaceutical companies looking for innovative new products. A licensing deal will ensure that the development of this promising, innovative drug will continue in a fast and efficient way to reach patients with this debilitating disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCRXF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCRXF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

PestiSi (2019)

Cost effective solution against insects in long-term grain storage by natural diatomaceous earth

Read More